M4MM

Otsuka Completes $1.23B Buyout of Transcend Therapeutics

PRINCETON – Otsuka America, the U.S. subsidiary of Otsuka Pharmaceutical Co., Ltd., announced that it has completed its acquisition of Transcend Therapeutics, a New York biotechnology company developing rapid-acting treatments for neuropsychiatric disease. First disclosed ...

Otsuka Completes $1.23B Buyout of Transcend Therapeutics

PRINCETON – Otsuka America, the U.S. subsidiary of Otsuka Pharmaceutical Co., Ltd., announced that it has completed its acquisition of Transcend Therapeutics, a New York biotechnology company developing rapid-acting treatments for neuropsychiatric disease. First disclosed ...

Glass House Brands Applies for NYSE Uplisting

LONG BEACH – Glass House Brands Inc., a vertically integrated Cannabis company concentrated in California, announced it has applied to list its subordinate voting shares on the New York Stock Exchange. The filing is among ...

Otsuka Completes $1.23B Buyout of Transcend Therapeutics

PRINCETON – Otsuka America, the U.S. subsidiary of Otsuka Pharmaceutical Co., Ltd., announced that it has completed its acquisition of Transcend Therapeutics, a New York biotechnology company developing rapid-acting treatments for neuropsychiatric disease. First disclosed ...

Otsuka Completes $1.23B Buyout of Transcend Therapeutics

PRINCETON – Otsuka America, the U.S. subsidiary of Otsuka Pharmaceutical Co., Ltd., announced that it has completed its acquisition of Transcend Therapeutics, a New York biotechnology company developing rapid-acting treatments for neuropsychiatric disease. First disclosed ...

Glass House Brands Applies for NYSE Uplisting

LONG BEACH – Glass House Brands Inc., a vertically integrated Cannabis company concentrated in California, announced it has applied to list its subordinate voting shares on the New York Stock Exchange. The filing is among ...

Optimi Ships Psilocybin to the UK for Phase 2 Trial

VANCOUVER – Optimi Health Corp. announced it has completed its first export of naturally derived psilocybin to the United Kingdom, with the material earmarked for a planned Phase 2 clinical trial whose partner and therapeutic ...

Subscribe To Our Newsletter